{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:09:00Z","timestamp":1761970140688,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.taap.2012.09.010","type":"journal-article","created":{"date-parts":[[2012,9,19]],"date-time":"2012-09-19T11:15:15Z","timestamp":1348053315000},"page":"343-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Improved preclinical cardiovascular therapeutic indices with long-term inhibition of norepinephrine reuptake using reboxetine"],"prefix":"10.1016","volume":"264","author":[{"given":"Anthony A.","family":"Fossa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd A.","family":"Wisialowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Cremers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke","family":"van der Hart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Rollema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen Q.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2012.09.010_bb0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00213-002-1146-7","article-title":"Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: preliminary data","volume":"163","author":"Agelink","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.taap.2012.09.010_bb0010","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/01.CIR.0000036370.31856.73","article-title":"Paradoxical effect of sibutramine on autonomic cardiovascular regulation","volume":"106","author":"Birkenfeld","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.taap.2012.09.010_bb0015","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/jps.2600730617","article-title":"Fluid shifts and other factors affecting plasma protein binding of prednisolone oby equilibrium dialysis","volume":"73","author":"Boudinot","year":"1984","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.taap.2012.09.010_bb0030","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/sj.npp.1301287","article-title":"Augmentation of SSRI effects on serotonin by 5-HT(2C) antagonists: mechanistic studies","volume":"32","author":"Cremers","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.taap.2012.09.010_bb0035","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/10641969409067952","article-title":"Chronic monitoring of cardiovascular function in the conscious guinea pig using radio-telemetry","volume":"16","author":"DePasquale","year":"1994","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.taap.2012.09.010_bb0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejphar.2003.12.028","article-title":"Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig","volume":"486","author":"Fossa","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.taap.2012.09.010_bb0045","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.vascn.2006.03.007","article-title":"Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants","volume":"55","author":"Fossa","year":"2007","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2012.09.010_bb0050","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/01.CIR.57.3.549","article-title":"The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris","volume":"57","author":"Gobel","year":"1978","journal-title":"Circulation"},{"key":"10.1016\/j.taap.2012.09.010_bb0055","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1097\/00004872-200110000-00003","article-title":"Renin-angiotensin-sympathetic crosstalk in hypertension: reappraising the relevance of peripheral interactions","volume":"19","author":"Grassi","year":"2001","journal-title":"J. Hypertens."},{"key":"10.1016\/j.taap.2012.09.010_bb0060","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.2011.1830","article-title":"ADHD medications and risk of serious cardiovascular events in young and middle-aged adults","volume":"306","author":"Habel","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.taap.2012.09.010_bb0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1527-3458.2004.tb00002.x","article-title":"The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile","volume":"10","author":"Haj\u00f3s","year":"2004","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.taap.2012.09.010_bb0075","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/sj.bjp.0703821","article-title":"Chronic treatment with reboxetine by osmotic pumps facilitates its effect on extracellular noradrenaline and may desensitize alpha(2)-adrenoreceptors in prefrontal cortex","volume":"132","author":"Invernizzi","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2012.09.010_bb0080","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.ijo.0802887","article-title":"Influence of sibutamine on blood pressure: evidence from placebo-controlled trials","volume":"29","author":"Jordan","year":"2005","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.taap.2012.09.010_bb0085","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0022-3565(24)29415-5","article-title":"S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine","volume":"298","author":"Millan","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9590","key":"10.1016\/j.taap.2012.09.010_bb0090","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0140-6736(07)61415-9","article-title":"Depression, chronic diseases, and decrements in health: results from the World Health Surveys","volume":"370","author":"Moussavi","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.taap.2012.09.010_bb0095","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2174\/0929867305666220319103330","article-title":"Review of cardiovascular effects of flozetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants","volume":"5","author":"Pacher","year":"1998","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.taap.2012.09.010_bb0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0893-133X(02)00301-9","article-title":"Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal, cortex","volume":"27","author":"Page","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.taap.2012.09.010_bb0105","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/01.RES.87.12.1157","article-title":"Role of structural barriers in the mechanism of alternans-induced reentry","volume":"87","author":"Pastore","year":"2000","journal-title":"Circ. Res."},{"key":"10.1016\/j.taap.2012.09.010_bb0110","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/HCO.0b013e3281ead011","article-title":"Depression and ischemic heart disease: what have we learned from clinical trials?","volume":"22","author":"Rivelli","year":"2007","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.taap.2012.09.010_bb0115","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1046\/j.0953-816x.2001.01583.x","article-title":"Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons","volume":"13","author":"Szabo","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.taap.2012.09.010_bb0120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF03160963","article-title":"Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest","volume":"4","author":"Tarabar","year":"2008","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.taap.2012.09.010_bb0125","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.jcp.0000155815.44338.95","article-title":"Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine","volume":"25","author":"Thase","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.taap.2012.09.010_bb0130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1124\/jpet.106.101881","article-title":"Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability","volume":"318","author":"Wisialowski","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X12004061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X12004061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:41:41Z","timestamp":1758573701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X12004061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0041008X12004061"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2012.09.010","relation":{},"ISSN":["0041-008X"],"issn-type":[{"type":"print","value":"0041-008X"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved preclinical cardiovascular therapeutic indices with long-term inhibition of norepinephrine reuptake using reboxetine","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2012.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}